Document is current
Any future updates will be listed below
-
Authors
Gill, Harinder
Raghupathy, Radha
Lee, Carmen Y.Y.
Yung, Yammy
Chu, Hiu-Tung
Ni, Michael Y.
Xiao, Xiao
Flores, Francis P.
Yim, Rita
Lee, Paul
Chin, Lynn
Li, Vivian W.K.
Au, Lester
Au, Wing-Yan
Ma, Edmond S.K.
Mohan, Diwakar
Kumana, Cyrus Rustam
Kwong, Yok-Lam
-
Funding
Funding for this research was provided by:
Food and Health Bureau (08191946)
- License Information
-
More Information
Article History
Received: 20 October 2022
Accepted: 6 February 2023
First Online: 10 February 2023
Declarations
:
: The study was approved by the Institutional Review Board of the University of Hong Kong/Hong Kong West Cluster (UW 19–873) and the study was carried out in accordance to the Declaration of Helsinki. Informed consent was obtained from all subjects and/or their legal guardian(s).
: Not applicable.
: Conflict-of-interest disclosure: The University of Hong Kong holds two Unites States of America patents (US 7,521,071 B2) (US patent 8,906,422 B2), one Japan patent (4786341) and one European patent (EP 1562616 B1) for the use of oral arsenic trioxide in the treatment of leukemias and lymphomas. H. Gill, C.R. Kumana and Y.L. Kwong are associated with the University of Hong Kong. None of the other authors have any conflicts of interest to declare.
